[go: up one dir, main page]

FR2876910B1 - Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction - Google Patents

Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Info

Publication number
FR2876910B1
FR2876910B1 FR0411202A FR0411202A FR2876910B1 FR 2876910 B1 FR2876910 B1 FR 2876910B1 FR 0411202 A FR0411202 A FR 0411202A FR 0411202 A FR0411202 A FR 0411202A FR 2876910 B1 FR2876910 B1 FR 2876910B1
Authority
FR
France
Prior art keywords
mequitazine
cyclodextrin
complex
interaction agent
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0411202A
Other languages
English (en)
Other versions
FR2876910A1 (fr
Inventor
Bernard Freiss
Hubert Lochard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0411202A priority Critical patent/FR2876910B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to EP05801647A priority patent/EP1802348A2/fr
Priority to NZ555238A priority patent/NZ555238A/en
Priority to RU2007118640/15A priority patent/RU2389491C2/ru
Priority to BRPI0516233-5A priority patent/BRPI0516233A/pt
Priority to AU2005296875A priority patent/AU2005296875B2/en
Priority to CA2583783A priority patent/CA2583783C/fr
Priority to PCT/EP2005/055388 priority patent/WO2006042857A2/fr
Priority to US11/665,839 priority patent/US7749982B2/en
Priority to KR1020077010998A priority patent/KR101273840B1/ko
Priority to MX2007004787A priority patent/MX2007004787A/es
Priority to CN2005800358701A priority patent/CN101043908B/zh
Priority to JP2007537271A priority patent/JP5157447B2/ja
Priority to TW094136627A priority patent/TWI372759B/zh
Priority to ARP050104407A priority patent/AR051593A1/es
Publication of FR2876910A1 publication Critical patent/FR2876910A1/fr
Priority to IL182412A priority patent/IL182412A/en
Application granted granted Critical
Publication of FR2876910B1 publication Critical patent/FR2876910B1/fr
Priority to ZA200703080A priority patent/ZA200703080B/en
Priority to NO20072433A priority patent/NO20072433L/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR0411202A 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction Expired - Fee Related FR2876910B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0411202A FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
CN2005800358701A CN101043908B (zh) 2004-10-21 2005-10-19 含有美喹他嗪、环糊精和相互作用试剂的络合物
RU2007118640/15A RU2389491C2 (ru) 2004-10-21 2005-10-19 Комплекс, содержащий меквитазин (mequitazine), циклодекстрин и агент взаимодействия
BRPI0516233-5A BRPI0516233A (pt) 2004-10-21 2005-10-19 complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral
AU2005296875A AU2005296875B2 (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
CA2583783A CA2583783C (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
PCT/EP2005/055388 WO2006042857A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US11/665,839 US7749982B2 (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
KR1020077010998A KR101273840B1 (ko) 2004-10-21 2005-10-19 메퀴타진, 시클로덱스트린 및 상호 작용제를 포함하는복합체
JP2007537271A JP5157447B2 (ja) 2004-10-21 2005-10-19 メキタジンとシクロデキストリンと相互作用剤を含む複合体
EP05801647A EP1802348A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
NZ555238A NZ555238A (en) 2004-10-21 2005-10-19 Complex containing mequitazine, a cyclodextrin and an interaction agent
MX2007004787A MX2007004787A (es) 2004-10-21 2005-10-19 Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion.
TW094136627A TWI372759B (en) 2004-10-21 2005-10-20 A complex comprising mequitazine, a cyclodextrin, and an interaction agent
ARP050104407A AR051593A1 (es) 2004-10-21 2005-10-21 Un complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion
IL182412A IL182412A (en) 2004-10-21 2007-04-10 A mequitazine, cyclodextrin and l-arginine conjugate as an interaction mediator, a method of preparation, a pharmaceutical containing it and a conjugate for use as a drug
ZA200703080A ZA200703080B (en) 2004-10-21 2007-04-16 Complex containing mequitazine, a cyclodextrin and an interaction agent
NO20072433A NO20072433L (no) 2004-10-21 2007-05-11 Kompleks som bestar av mekitazin, et syklodekstrin og et interaksjonsmiddel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411202A FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Publications (2)

Publication Number Publication Date
FR2876910A1 FR2876910A1 (fr) 2006-04-28
FR2876910B1 true FR2876910B1 (fr) 2007-04-13

Family

ID=34949969

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0411202A Expired - Fee Related FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Country Status (18)

Country Link
US (1) US7749982B2 (fr)
EP (1) EP1802348A2 (fr)
JP (1) JP5157447B2 (fr)
KR (1) KR101273840B1 (fr)
CN (1) CN101043908B (fr)
AR (1) AR051593A1 (fr)
AU (1) AU2005296875B2 (fr)
BR (1) BRPI0516233A (fr)
CA (1) CA2583783C (fr)
FR (1) FR2876910B1 (fr)
IL (1) IL182412A (fr)
MX (1) MX2007004787A (fr)
NO (1) NO20072433L (fr)
NZ (1) NZ555238A (fr)
RU (1) RU2389491C2 (fr)
TW (1) TWI372759B (fr)
WO (1) WO2006042857A2 (fr)
ZA (1) ZA200703080B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
JP7029886B2 (ja) * 2017-04-28 2022-03-04 ロート製薬株式会社 医薬組成物及びその製造方法
KR20220085094A (ko) 2020-12-14 2022-06-22 메디케어제약 주식회사 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (fr) 1969-03-03 1971-10-20
FR2522660A1 (fr) * 1982-03-05 1983-09-09 Pharmuka Lab Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
JP2735122B2 (ja) 1988-06-13 1998-04-02 旭化成工業株式会社 メキタジンの液状シロップ製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
RU2097025C1 (ru) * 1990-11-06 1997-11-27 Ниппон Синяку Компани, Лимитед Лиофилизированный препарат жировой эмульсии и способ его получения
TW262497B (en) 1994-06-29 1995-11-11 Toshiba Co Ltd Washing machine
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
JPH10167954A (ja) * 1996-12-05 1998-06-23 Takada Seiyaku Kk メキタジン製剤
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
FR2830760B1 (fr) 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
JP5091661B2 (ja) 2004-04-01 2012-12-05 ピエール ファーブル メディカモン 超臨界ｃｏ２と錯体相互作用剤を用いる方法によって得られる包接錯体

Also Published As

Publication number Publication date
CN101043908B (zh) 2011-11-16
AU2005296875B2 (en) 2011-03-31
US20070293454A1 (en) 2007-12-20
TW200621770A (en) 2006-07-01
MX2007004787A (es) 2007-05-15
US7749982B2 (en) 2010-07-06
IL182412A0 (en) 2007-07-24
KR20070084223A (ko) 2007-08-24
KR101273840B1 (ko) 2013-06-11
IL182412A (en) 2015-02-26
AU2005296875A1 (en) 2006-04-27
CN101043908A (zh) 2007-09-26
JP5157447B2 (ja) 2013-03-06
BRPI0516233A (pt) 2008-08-26
NZ555238A (en) 2010-04-30
WO2006042857A2 (fr) 2006-04-27
RU2007118640A (ru) 2008-11-27
EP1802348A2 (fr) 2007-07-04
AR051593A1 (es) 2007-01-24
NO20072433L (no) 2007-05-11
JP2008517035A (ja) 2008-05-22
CA2583783C (fr) 2013-05-21
TWI372759B (en) 2012-09-21
CA2583783A1 (fr) 2006-04-27
ZA200703080B (en) 2008-05-28
RU2389491C2 (ru) 2010-05-20
WO2006042857A3 (fr) 2006-07-27
FR2876910A1 (fr) 2006-04-28

Similar Documents

Publication Publication Date Title
EP1789709A4 (fr) Robinet d'arret
DE602005003619D1 (de) Teilchenförmiges Mattierungsmittel
EP1762234A4 (fr) Activateur d'ampk
LTC1694363I2 (lt) Monodispersinės pegiliuoto naloksolio kompozicijos
EP1962961A4 (fr) Demi-corps : agents thérapeutiques activés par dimérisation
MA29014B1 (fr) Formulations d'anticorps
FR2877214B1 (fr) Composition capillaire epaissie comprenant un polyurethane de haut poids moleculaire
FR2866617B1 (fr) Plancher elastique et couloir d'intercirculation le comprenant
ITPN20050014A1 (it) "piedino livellatore perfezionato"
EP2111484A4 (fr) Agent de brillance polyamine
EP1768685A4 (fr) Compositions cosmetiques comprenant rhodiola rosea et leurs procedes
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
DE602004003239D1 (de) Kippsegmentlageranordnung
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
FR2892743B1 (fr) Moyens d'assemblage de jambe d'appui d'echafaudage, jambe d'appui et echafaudage comprenant de tels moyens
FR2876910B1 (fr) Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
FR2888748B1 (fr) Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
FR2877713B3 (fr) Structure d'abat-jour pliable.
FR2876911B1 (fr) Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
EP1894574A4 (fr) Agent anticancereux comprenant un inhibiteur de la proteine c
NO20042486L (no) Novel contrast agent
FR2870738B1 (fr) Composition cosmetique comprenant des microspheres
DE502005006114D1 (de) Gebläse
DE502005007301D1 (de) Gebläse
EP1747205A4 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20170630